Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tinzaparin vs placebo Pain intensityNumeric pain scale · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | 1 study · 253 participants | Very low |
Dalteparin vs placebo Pain intensityVAS 0‐10. Scale from: 0 to 10. · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | 1 study · 35 participants | Very low |
Dalteparin vs placebo Pain duration ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo The requirement for opiate treatment ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Number of serious complications of SCD ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Number of other sickle‐related events ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Hospitalisation (number and duration) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs placebo Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · patients with people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Pain durationScale from: 1 to 7. · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | 1 study · 253 participants | Very low |
Tinzaparin vs placebo The requirement for opiate treatment · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | 1 study · 253 participants | Very low |
Tinzaparin vs placebo Number of serious complications of SCD ‐ not measured · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Number of other sickle‐related events ‐ not measured · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Hospitalisation (number and duration)Scale from: 0 to 12. · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | 1 study · 253 participants | Very low |
Tinzaparin vs placebo Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | no estimate extracted | NR | No studies |
Tinzaparin vs placebo Adverse events associated with the use of anticoagulants (e.g. bleeding) · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane | RR 4.96 [0.24, 102.31] | 1 study · 253 participants | Low |
Deferasirox vs deferoxamine Mortality · patients with sickle cell disease and transfusional iron overload Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane | RR 1.26 [0.05, 30.41] | 1 study · 191 participants | Very low |
Deferasirox vs deferoxamine End‐organ damage (incidence of diabetes) · patients with sickle cell disease and transfusional iron overload Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane | RR 1.26 [0.05, 30.41] | 1 study · 191 participants | Very low |
Deferasirox vs deferoxamine LIC measured by SQUID biomagnetometer (mg Fe/g dw); overall population adjusted for transfusion category · patients with sickle cell disease and transfusional iron overload Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane | no estimate extracted | 1 study · 173 participants | Moderate |
Deferasirox vs deferoxamine Serum ferritin (µg/l) · patients with sickle cell disease and transfusional iron overload Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane | no estimate extracted | 2 studies · 283 participants | Moderate |
Deferasirox vs deferoxamine AE: Change in creatinine from baseline (µmol/l) · patients with sickle cell disease and transfusional iron overload Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane | no estimate extracted | 1 study · 195 participants | Moderate |
Deferasirox vs deferoxamine Discontinuations · patients with sickle cell disease and transfusional iron overload Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane | RR 0.53 [0.31, 0.92] | 2 studies · 398 participants | Low |
Deferasirox vs deferoxamine Satisfaction · patients with sickle cell disease and transfusional iron overload Deferasirox for managing transfusional iron overload in people with sickle cell disease (2014) · Cochrane | RR 3.13 [1.99, 4.93] | 1 study · 195 participants | Moderate |
Intervention NR Total ITI Success · persons with severe haemophilia A and factor inhibitory antibodies Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B (2014) · Cochrane | RR 1.07 [0.68, 1.68] | 1 study · 115 participants | Moderate |
Intervention NR All bleeding events · persons with severe haemophilia A and factor inhibitory antibodies Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B (2014) · Cochrane | RR 1.36 [1.09, 1.71] | 1 study · 115 participants | Low |
Intervention NR CVAD infections · persons with severe haemophilia A and factor inhibitory antibodies Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B (2014) · Cochrane | RR 0.96 [0.6, 1.53] | 1 study · 99 participants | Moderate |
Intervention NR Severe allergic reaction · persons with severe haemophilia A and factor inhibitory antibodies Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Nephrotic symdrome · persons with severe haemophilia A and factor inhibitory antibodies Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B (2014) · Cochrane | no estimate extracted | NR | No studies |